Projects per year
Fingerprint
Dive into the research topics where Ramesk K Ramanathan is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
Projects
- 1 Finished
-
NCI Experimental Therapeutics-Clinical Trials Network with Phase 1 Emphasis
Adjei, A., Erlichman, C., Haluska, P. R. J. & Ramanathan, R. K.
4/7/14 → 2/28/21
Project: Research project
-
Multicohort Retrospective Validation of a Predictive Biomarker for Topoisomerase I Inhibitors
Ando, K., Ozonoff, A., Lee, S. Y., Voisine, M., Parker, J. T., Nakanishi, R., Nishimura, S., Yang, J., Grace, Z., Tran, B., Diefenbach, T. J., Maehara, Y., Yasui, H., Irino, T., Salgia, R., Terashima, M., Gibbs, P., Ramanathan, R. K., Oki, E., Mori, M., & 3 others, Jun 2021, In: Clinical colorectal cancer. 20, 2, p. e129-e138Research output: Contribution to journal › Article › peer-review
-
Phase I Open-Label Study Evaluating the Safety, Pharmacokinetics, and Preliminary Efficacy of Dilpacimab in Patients with Advanced Solid Tumors
Gordon, M. S., Nemunaitis, J., Barve, M., Wainberg, Z. A., Hamilton, E. P., Ramanathan, R. K., Sledge, G. W., Yue, H., Morgan-Lappe, S. E., Blaney, M., Kasichayanula, S., Motwani, M., Wang, L., Naumovski, L. & Strickler, J. H., Oct 2021, In: Molecular cancer therapeutics. 20, 10, p. 1988-1995 8 p.Research output: Contribution to journal › Article › peer-review
Open Access -
Correction to: Phase Ib Trial of the PI3K Inhibitor Copanlisib Combined with the Allosteric MEK Inhibitor Refametinib in Patients with Advanced Cancer (Targeted Oncology, (2020), 15, 2, (163-174), 10.1007/s11523-020-00714-0)
Ramanathan, R. K., Von Hoff, D. D., Eskens, F., Blumenschein, G., Richards, D., Genvresse, I., Reschke, S., Granvil, C., Skubala, A., Peña, C. & Mross, K., Dec 2020, In: Targeted Oncology. 15, 6, p. 803 1 p.Research output: Contribution to journal › Comment/debate › peer-review
Open Access -
Nomogram for Estimating Overall Survival in Patients with Metastatic Pancreatic Cancer
Goldstein, D., Von Hoff, D. D., Chiorean, E. G., Reni, M., Tabernero, J., Ramanathan, R. K., Botteman, M., Aly, A., Margunato-Debay, S., Lu, B., Louis, C. U., McGovern, D. & Lee, C. K., Jul 1 2020, In: Pancreas. 49, 6, p. 744-750 7 p.Research output: Contribution to journal › Article › peer-review
Open Access -
Phase 2 study of vismodegib, a hedgehog inhibitor, combined with gemcitabine and nab-paclitaxel in patients with untreated metastatic pancreatic adenocarcinoma
De Jesus-Acosta, A., Sugar, E. A., O’Dwyer, P. J., Ramanathan, R. K., Von Hoff, D. D., Rasheed, Z., Zheng, L., Begum, A., Anders, R., Maitra, A., McAllister, F., Rajeshkumar, N. V., Yabuuchi, S., de Wilde, R. F., Batukbhai, B., Sahin, I. & Laheru, D. A., Feb 18 2020, In: British journal of cancer. 122, 4, p. 498-505 8 p.Research output: Contribution to journal › Article › peer-review
Open Access25 Scopus citations